|
Location
(clinicaltrials.gov ID)
|
Title
|
Status
|
|
GIHU004
Hungary
(NCT00712530)
To read Study Synopsis click here...
|
A Phase I Study to Evaluate the Tolerability and Safety of DermaVir Immune Therapy in HIV-infected Subject under Treatment with HAART
|
Excellent safety, tolerability, and immunogenicity: DermaVir evoked long-lasting gag-specific T cells 6- to 18,000 fold above
pre-treatment values in all nine patients, in dose dependent manner.
|
|
ACTG 5176
USA
(NCT00270205)
To read Study Synopsis click here...
|
A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of DermaVir Patch Immune Therapy in HIV-infected Subjects Currently Under Treatment with HAART
|
24 of the 24 patients enrolled, the trial is still blinded.
|
|
GIEU006
Germany
(NCT00711230)
To read Study Synopsis click here...
|
A Phase II, Randomized, Study to Evaluate the Safety, Tolerability, Immunogenicity and Antiviral Activity of DermaVir Patch Immune Therapy in HIV-1 Infected treatment-naïve Subjects
|
36 of the 36 patients are enrolled. Trial so far shows excellent safety and tolerability, still blinded for efficacy.
|
|
PHPC-02
Italy
To read Study Synopsis click here...
|
Antiretroviral sparing concept: a Phase II, randomized, single blind placebo controlled study to investigate the effect of DermaVir immunization on the quantity of HIV-specific T cells during HAART followed by analytical treatment interruption
|
16 of the 16 patients enrolled, the trial is still blinded.
|
|
IMPAACT-P1049
USA
|
A Phase I/II study of the safety, tolerability and immunogenecity of a topical therapeutic DNA denritic cell vaccine (DermaVir Patch) in children, adolescents and young adults with hiv-1 infection on highly active antiretroviral therapy (HAART).
|
In preparation
|
|
